Shinichiro Fuse, PhD

Principal, MPM Capital

Shinichiro (Shin) Fuse, Ph.D., joined MPM as a Principal in 2016 and is engaged in MPM’s investment identification, due diligence and business development activities across our current BV2014 and OIF funds. He also supports MPM’s relationship with Astellas and is a board observer for Coda Biotherapeutics and Repare Therapeutics. Prior to joining MPM, Shin was Director of Business Development at bluebird bio, where he played an instrumental role in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy, and genome editing, including partnerships with Five Prime Therapeutics, Seattle Children’s Research Institute, and the acquisition of Pregenen. Before that, he was an Engagement Manager at Campbell Alliance (inVentiv Health Consulting), an Associate at PureTech Ventures, and a columnist and contributing writer for Nikkei Biotech, the leading journal covering the biotech industry in Japan.

Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, a M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.

Board ObserversFiona Sloan